Digest Network Come funziona
Network
/
Società
Ya
Non verificato

Yarrow Bioscience, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaFinanzaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Finanza
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0
11/09/2026
Finanza
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0
10/09/2026
Finanza
Biotecnologia
Salute
Ottica
Sanità
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0
13/08/2026
Mercato azionario
Biotecnologia
Salute
Medicina - Varie
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0
27/07/2026
Mercato azionario
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0
15/12/2025
Mercato del lavoro
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
GenSci and RTW Investments Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience
Fonte
Yarrow Bioscience, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0